Business Context and Reporting Period
This Form 8-K is filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) for the reporting period ending December 15, 2017. The filing discloses significant executive personnel changes and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and equity awards.
Material Changes
- Executive Departure: Thomas C. Varvaro entered into a separation agreement to resign effective January 19, 2018.
- Compensation Adjustment: Robert Fried, President and Chief Strategy Officer, had his employment agreement amended to eliminate future time-based stock grants in favor of performance-based grants tied to a change in control.
- Equity Acceleration: The Compensation Committee accelerated the vesting of 166,667 restricted shares for Mr. Fried and granted an additional 333,333 fully-vested restricted shares.
Outlook, Risks, and Unusual Items
Separation Terms for Thomas C. Varvaro:
- Continued base salary for 24 months post-separation.
- Maximum fiscal year 2017 cash bonus.
- COBRA, long-term disability, and life insurance premiums paid for 24 months.
- Acceleration of vesting for all outstanding options and equity awards.
- Consulting services available for three months post-separation (up to 24 hours/month).
Amendment for Robert Fried:
- Future equity grants are now contingent on a change in control.
- Immediate grant of 500,000 total restricted shares (166,667 accelerated + 333,333 new).
Risks and Contingencies: The compensation benefits for Mr. Varvaro are subject to the Company receiving an effective release and waiver of claims.
Investor Verification Checklist
- Verify the total cost of the separation package for Thomas C. Varvaro, including the specific value of accelerated equity.
- Confirm the impact of the 500,000 share grant to Robert Fried on the company's share count and dilution.
- Review the attached Exhibits 10.1 and 10.2 for full legal terms of the separation and employment amendment.
- Assess the strategic implications of eliminating time-based equity grants for the President and Chief Strategy Officer.